Antonio Fernández‐Nebro

Author

Hospital Regional Universitario de Málaga ORCID

Also Known As

A Fernandez Nebro, A Fernandez-Nebro, A Fernández Nebro, A Fernández-Nebro, A. Fernandez Nebro, A. Fernandez-Nebro, A. Fernández Nebro, A. Fernández-Nebro, A. Fernández‐Nebro, A.F. Nebro

388

Publications

12.2K

Citations

H-Index

Concepts

All Affiliations

Hospital Regional Universitario de Málaga Universidad de Málaga Instituto de Investigación Biomédica de Málaga Hospital Universitario de La Princesa Hospital Clínico Universitario Virgen de la Victoria

About

Antonio Fernández‐Nebro is an author at Hospital Regional Universitario de Málaga specializing in medicine, autoimmune disease, and rheumatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	30	2.3K
2	Epidemiology	11	11	588
3	Public Health	10	10	572
4	Allergy	3	3	69
5	Global Health	1	1	41

Antonio Fernández‐Nebro

108

Publications

10.7K

Citations

H-Index

Page 1

	Year	Citations
Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients Ricard Cervera, Jean‐Charles Piette, Josep Font, Arthritis & Rheumatism	2002	2.1K
Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period Ricard Cervera, Munther A. Khamashta, Josep Font, Medicine	2003	1.4K
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients Ricard Cervera, Rosa Serrano, Guillermo Pons‐Estel, Annals of the Rheumatic Diseases	2014	941
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial Roy Fleischmann, Eduardo Mysler, Stephen Hall, The Lancet Rheumatoid DisorderRheumatologyTofacitinib MonotherapyMedicineRheumatic Diseases	2017	479
Morbidity and Mortality in Systemic Lupus Erythematosus During a 5-Year Period: A Multicenter Prospective Study of 1,000 Patients Ricard Cervera, Munther A. Khamashta, Josep Font, Medicine	1999	430
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial Peter Nash, Bruce Kirkham, Masato Okada, The Lancet Rheumatoid DisorderRheumatologySpirit-p2 Phase 3Autoimmune DiseaseMedicine	2017	390
Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients Ricard Cervera, Munther A. Khamashta, Y Shoenfeld, Annals of the Rheumatic Diseases	2008	283
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study José L. Pablos, María Galindo-Izquierdo, Loreto Carmona, Annals of the Rheumatic Diseases	2020	235
Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis Maureen D. Mayes, Lara Bossini‐Castillo, Olga Y. Gorlova, The American Journal of Human Genetics Autoimmune DiseaseMedicineImmunologySystemic SclerosisAutoimmunity	2014	204
A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility F. David Carmona, Sarah Mackie, Jose‐Ezequiel Martín, The American Journal of Human Genetics	2015	174

Page 1